MiniMed Group Inc. Common Stock vs 22nd Century Group Inc — how do they compare? MiniMed Group Inc. Common Stock trades at $19.66 (market cap $5.57B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: MiniMed Group Inc. Common Stock is far larger — about 8959.7× 22nd Century Group Inc's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 1 Days and 22nd Century Group Inc for 32 Days on average.
| MMED | XXII | |
|---|---|---|
Market Cap | $5.57B | $621.67K |
Volume | 23,336,073 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $23.84 | $483.00 |
52-Week Low | $10.80 | $0.80 |
Typical Hold Time | 1 Days | 32 Days |
Enterprise Value | $5.37B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →